key: cord-0786369-d2fc2kw5
authors: Rane, M. S.; Robertson, M.; Kulkarni, S.; Frogel, D.; Gainus, C.; Nash, D.
title: Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting
date: 2022-02-22
journal: nan
DOI: 10.1101/2022.02.21.22271298
sha: 19f31e91712acc9f5c70327e4ef7f2f629e19402
doc_id: 786369
cord_uid: d2fc2kw5

Background It is critical to monitor changes in vaccine effectiveness against COVID 19 outcomes for various vaccine products in different population subgroups. Methods We conducted a retrospective study in patients [≥]12 years who underwent testing for the SARS CoV 2 virus from April 1 to October 25, 2021 at urgent care centers in the New York City metropolitan area. Patients self reported vaccination status at the time of testing. We used a test negative design to estimate vaccine effectiveness (VE) by comparing odds of a positive test for SARS CoV 2 infection among vaccinated (n=484,468), partially vaccinated (n=107,573), and unvaccinated (n=466,452) patients, adjusted for demographic factors and calendar time. Results VE against symptomatic infection after 2 doses of mRNA vaccines was 96% (95% Confidence Interval [CI]: 95%, 97%) in the pre-delta period and reduced to 79% (95% CI: 77%, 81%) in the delta period. In the delta period, VE for 12 to 15 year olds (85%; [95% CI: 81%, 89%]) was higher compared to older age groups (<65% for all other age groups). VE estimates did not differ by sex, race/ethnicity, and comorbidity. VE against symptomatic infection was the highest for individuals with a prior infection followed by full vaccination. VE against symptomatic infection after the mRNA1273 vaccine (83% [95% CI: 81%, 84%]) was higher compared to the BNT162b2 vaccine (76% [95% CI: 74%, 78%]) in the delta period. VE after the single-dose Ad26.COV2.S vaccine was the lowest compared to other vaccines (29% [95% CI: 26%, 32%]) in the delta period . Conclusions VE against infection after two doses of the mRNA vaccine was high initially, but significantly reduced against the delta variant for all three FDA approved vaccines.

As of February 9, 2022, the COVID-19 pandemic has claimed 5.7 million lives globally, with over ~912,000 deaths reported in the United States (US) 1 . Vaccines remain the most effective public health tool against COVID-19 morbidity and mortality. In the US, the Pfizer-BioNTech BNT162b2 2 vaccine and the Moderna mRNA-1273 vaccine 3 are fully approved and the Janssen Ad26.COV2.S vaccine 4 is currently authorized for emergency use. All three vaccines have shown high efficacy against severe disease and mortality in clinical trials against the alpha and delta variants of SARS-CoV-2 virus 3,5-7 . In November 2021, the highly transmissible B.1.1.529 (Omicron) variant was declared as a variant of concern by the World Health Organization. While evidence of vaccine effectiveness against this variant is still evolving, data from South Africa and UK indicate that mRNA All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

vaccines continue to be effective against serious disease and hospitalization caused the by Omicron variant, particularly among those who were boosted with a third dose 8,9 . Observational studies have consistently found high vaccine effectiveness against death and severe disease [11] [12] [13] [14] [15] [16] [17] for all three vaccines. However, vaccine effectiveness against COVID-19 infection has declined over time, especially since the delta variant emerged as the predominant strain 11, 12, [17] [18] [19] [20] [21] [22] [23] [24] . As the SARS-CoV-2 virus continues to evolve and more variants emerge 25 , monitoring changes in vaccine effectiveness against COVID-19 outcomes for various vaccine products in different population subgroups is of utmost importance.

In this study, we used a test-negative case-control design 26 , comparing vaccination status among people who test positive (cases) and negative (controls), to estimate vaccine effectiveness (VE) against symptomatic and asymptomatic SARS-CoV-2 infection over time in a population of patients seeking care at CityMD, a large ambulatory care center in NYC and neighboring areas. We also compared vaccine-induced and infection-induced protection against SARS-CoV-2 by vaccine product.

We conducted a test-negative case control study to estimate vaccine effectiveness of different COVID-19 vaccines among residents of New York City and surrounding metropolitan area who received a polymerase chain reaction (PCR) test or a rapid antigen test for SARS-CoV-2 at one of the 115 CityMD New York locations in the five boroughs of NYC (n=76), Long Island, NY (n=32), and Westchester, NY (n=7). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Exposure and outcome measures COVID-19 vaccination: Data on COVID-19 vaccination status was systematically ascertained via patient self-report as part of their intake and history. At the time of testing, patients reported whether they received a COVID-19 vaccine, the vaccine manufacturer, and whether two weeks have elapsed since their final dose. Patients who reported receiving only one dose of the mRNA vaccines or 2 doses within 2 weeks of the day of testing were defined as partially vaccinated. Those receiving 2 doses of the mRNA vaccine at least 2 weeks before testing were defined as fully-vaccinated.

Testing for SARS-CoV-2 conducted at CityMD using assays authorized by the Food and Drug Administration (FDA), included: PCR tests of respiratory tract specimens for SARS-CoV-2 RNA collected via nasopharyngeal and nasal swabs and rapid antigen tests of respiratory tract specimens collected via anterior nasal swabs. All patients were evaluated by a licensed clinician.

Symptomatic and Asymptomatic SARS-CoV-2 Infection: We defined symptomatic COVID-19 as SARS-CoV-2 positive patients who exhibited at least one of these symptoms: fever, oxygen saturation < 95%, chills, cough, headache, fatigue, myalgia, sore throat, chest tightness, shortness of breath, loss All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 22, 2022. ; https://doi.org/10.1101/2022.02.21.22271298 doi: medRxiv preprint of sense of taste and smell, nausea, vomiting, diarrhea, chest pain, confusion/altered mental state. If no symptoms were recorded in the EMR, patients were considered asymptomatic. Date of visit was used as a proxy for the date of symptom onset.

Covariates: Patient age, sex, race/ethnicity, comorbidities, region of residence, and BMI were obtained from the EMR. Individuals with a higher likelihood of COVID-19 exposure are likely to undergo serial testing. Therefore, the total number of tests performed at CityMD before April 1, 2021, were used as proxy for individuals with higher exposure to SARS-CoV-2. We assumed that the absence of information on comorbidities, symptoms, and previous tests in the EMR meant that none were present.

Statistical analysis: Chi-squared test was used to compare characteristics between test positive cases and test negative controls and between vaccinated and unvaccinated testers. Multivariable logistic regression was used to estimate the odds ratio (OR) of vaccination comparing cases and controls. VE was calculated as (1-OR) x 100%. ORs were adjusted for the covariates listed above, selected a priori as potential confounders. To account for temporal confounding due to increasing vaccine coverage, different timing of vaccine eligibility for different age groups, and changing SARS-CoV-2 incidence over time, we adjusted the models for calendar time grouped in 2-week intervals 28 .

Vaccine effectiveness for mRNA vaccines. For the main analysis, we estimated VE for the 2-dose mRNA vaccines combined. Patients who received the one-dose Jannsen vaccine (6% of the study sample) were excluded. Patients tested positive at any time prior to April 1, 2021, by PCR, rapid test, or antibody tests conducted at CityMD clinics were also excluded. For all models, VE before the delta variant became predominant in the NYC area (April 1, 2021 -June 10, 2021, henceforth referred to as 'pre-delta period') and during delta variant predominance (June 11, 2021 -October 25, 2021, 'delta period') were compared. VE was also estimated stratified by age group (12-15 years, 16-30 years, 31-50 years, 51-64 years 65-80 years, >80 years), sex, presence of comorbidities, and race/ethnicity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Vaccine-induced and infection-induced protection by vaccine product. We compared vaccine-induced and infection-induced protection separately for each vaccine product (Pfizer-BioNTech BNT162b2, Moderna mRNA-1273, and Janssen Ad26.COV2.S), adjusted for the same covariates above. Patients with no vaccine-induced or infection-induced protection (reference group) were compared to patients with a previous infection but no vaccine (infection-induced protection only), previous infection + one or two doses of vaccine (hybrid protection), and one or two doses of vaccine but no previous infection (vaccine-induced protection only).

As a sensitivity analysis to assess whether the type of test used (RT-PCR vs. rapid antigen test) biased VE estimates, we estimated VE for 2-dose mRNA vaccines against any infection restricted to patients who received only the RT-PCR test. All analyses were conducted in R 4.0.1(Vienna, Austria). Tests were two-sided with P-value <0.05 considered significant.

The study sample included 1,058,493 individuals who contributed at least one COVID-19 RT-PCR or rapid antigen test between April 1, 2021 and October 25, 2021 ( Figure 1 ). The median age of study participants was 33 years (interquartile range, 25 -49). Patient characteristics by vaccination and SARS-CoV-2 infection status are described in Table 1 Vaccine effectiveness over time All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Figure 3 ).

Adjusted VE with 2-dose mRNA vaccines against any infection was higher in the pre-delta compared to delta period for all demographic subgroups. VE for ages 16 to 64 years was >85% in the pre-delta period vs. <65% in delta period. VE was lower for 64+ year olds compared with <64-year-olds, even in the pre-delta period. Compared to age groups older than 16 years, higher VE was observed for 12-15-year-olds (85%; [95% CI: 81%, 89%]) in the delta period. VE estimates were comparable across sex, race/ethnicity, and comorbidity groups in both pre-delta and delta period ( Figure 3 ). (Figure 4a, 4b, 4c ). Compared to those unvaccinated with no prior infections, those unvaccinated with prior infections had a 91% (95% CI: All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 ).

Using a test-negative case-control study design, we estimated vaccine effectiveness against symptomatic and asymptomatic SARS-CoV2 infection in a population of testers at urgent care centers in the NYC metropolitan area during the pre-delta and delta eras of the pandemic. We found that vaccine effectiveness after 2 doses of mRNA vaccines was very high (>90%) in the pre-delta period across subgroups of populations but declined over time. The mRNA-1273 vaccine was found to be slightly more effective compared to the BNT162b2 vaccine, while VE was much lower for recipients Because the study participants are restricted to those who attend an urgent care clinic for a test, the test-negative study design can potentially control for selection bias arising due to differences in healthcare-seeking behavior between cases and controls. Moreover, use of highly specific and sensitive molecular tests for case detection makes outcome misclassification less likely. 26 . This design has been popular for estimating COVID-19 vaccine effectiveness 12 The stark drop in VE in early July is contemporaneous with the rise in prevalence of the Delta variant in New York City, which accounted for 60% of all cases by the end of June 41 . Some studies posit that decrease in VE is likely to be due to lower effectiveness against the delta variant 5,39 , while others have attributed it to waning of vaccine effect 11,32,42 . As we did not have vaccination dates in our All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. VE against infection among >65-year-olds, as well as among those with comorbidities, had declined to under 60% by October 2021. These findings support CDC's recommendations to prioritize booster doses for these individuals, given their elevated risk of mortality and hospitalization 44 45 . VE was comparable across racial/ethnic groups, which is an important finding given the high burden of disease and the initially low COVID-19 vaccine acceptance in racial minorities in the US 46,47 . Recently, gaps in vaccination coverage by race/ethnicity have narrowed, with a majority of unvaccinated people in the US now being White 48 . Reporting vaccine effectiveness estimates by race/ethnicity can help to increase vaccine confidence among communities with low vaccine acceptance.

VE estimates comparing vaccine-induced and infection-induced protection from (re)-infection is scarce, complicated by the timing of vaccine roll-out in most populations less than a year into the pandemic. In line with other studies, we found that, in the pre-delta period, vaccine-induced and infection-induced protection were comparable for both mRNA vaccines, and vaccination following infection provided incremental protection against COVID-19 [49] [50] [51] . In the delta period, however, a history of infection was found to be more protective against re-infections compared to vaccination without prior infection, similar to evidence found in Israel and India 52, 53 , but in contrast to evidence from the US 54 . In our study, the relatively short average time since previous infection (7 months) could be the reason for higher protection among those with prior infection 51,55-57 .

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Individuals with previous infection and one dose of the either mRNA vaccine had high protection against re-infection, suggesting that the first dose of the mRNA vaccine may act like a booster for those who were previously infected 58 . Even so, full vaccination is still highly recommended for those with prior infection, because levels of protection can vary based on age and disease severity 59,60 , while VE is relatively uniform across populations, with the possible exception of older and immunocompromised individuals 61 . Furthermore, even mild disease can lead to long COVID-19 62, 63 .

Our study has limitations. Even though test-negative design controls for bias due to healthcareseeking behavior and access, the rates of testing between vaccinated and unvaccinated people might differ. Vaccinated individuals with symptoms could be more motivated to get tested which would lead to an overrepresentation of vaccinated individuals with positive test results, biasing the VE estimates downwards 64 . Bias due to unmeasured confounders, such as occupation or behavior changes following policies or vaccination is also possible 65,66 . We may have missed reports of prior infections if participants were tested at other clinics, which could also bias VE estimates downwards. Outcomes for patients who received only an antigen test could be misclassified due to lower test sensitivity.

However, our sensitivity analysis showed that when restricted to the highly sensitive RT-PCR tests results, VE estimates were nearly identical to those of the overall sample. Misclassification of exposure is a possibility as vaccination status was self-reported and dates of vaccination were not collected. However, other studies have shown very high agreement between self-reported and recorded COVID-19 vaccination status 67,68 . VE after one dose of mRNA vaccines is likely underestimated in this study because it was not known if the outcome occurred more than 15 days after the first dose. We did not collect information on disease severity and hospitalization and could not differentiate between asymptomatic and pre-symptomatic patients. These results are not generalizable to populations that do not seek healthcare at ambulatory clinics in NYC.

In conclusion, our analysis of urgent care visit data over a 7-month period showed high overall effectiveness after two doses of the mRNA vaccine in the pre-delta period, but significantly reduced vaccine effectiveness in the delta period for all three FDA-approved vaccines. Prior infection All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Tables All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Immunogenicity, and Efficacy of the BNT162b2 Covid-19

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529)

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Effectiveness of Covid-19 vaccines in the United States over 9 months: Surveillance data from the state of North Carolina

Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design

Pfizer-BioNTech Vaccine Effectiveness Against SARS-CoV-2 Infection: Findings From a Large Observational Study in Israel

The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data

COVID-19 Vaccination and Non--COVID-19 Mortality Risk-Seven Integrated Health Care Organizations, United States

Comparison of Two Highly-Effective mRNA Vaccines for COVID-19 During Periods of Alpha and Delta Variant Prevalence

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study

Waning Immunity after the BNT162b2 Vaccine in Israel

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel

Coronavirus Disease 2019 Case Surveillance -United States

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19

Hospitalization and Mortality among Black Patients and White Patients with Covid-19

Amanda Berry, Christian Grov, and Denis Nash for the CHASING COVID Cohort Study Team. Determinants and trends of COVID-19 vaccine hesitancy and vaccine uptake in a national cohort of U.S. adults: A longitudinal study

Latest Data on COVID-19 Vaccinations by Race/Ethnicity

Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic and Pooled Analysis

Coronavirus (COVID-19) Infection Survey Technical Article: Impact of vaccination on testing positive in the UK

SARS-CoV-2 infection rates of antibody-positive compared with antibodynegative health-care workers in England: a large, multicentre

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections

Protective Effect Conferred by Prior Infection and Vaccination on COVID-19 in a Healthcare Worker Cohort in South India

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity -Nine States

Persistence of neutralizing antibodies a year after SARS-CoV-2 infection

A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Significant reduction in humoral immunity among healthcare workers and nursing home residents 6 months after COVID-19 BNT162b2 mRNA vaccination

Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT

Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Patients

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Brooklyn 95513 (19.7%) 17946 (16.7%) 91166 (19.5%) 11082 (19.9%) 193543 (19.3%) Manhattan 150249

Symptomatic at rapid testing Yes 166539 (34.4%) 28099 (26.1%) 123838 (26.5%) <0.001 40371 (72.3%) 278105 (27.7%)

Comorbidities Yes 124805 (25.8%) 23253 (21.6%) 82885 (17.8%) <0.001 10719 (19.2%) 220224 (22.0%)

Obese 93216 (19.2%) 22035 (20.5%) 113364 (24.3%) 12984 (23.3%) 215631 (21.5%) Overweight 132707 (27.4%) 29496 (27.4%) 126685 (27.2%) 16221 (29.1%) 272667 (27.2%)

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted February 22, 2022. ; https://doi.org/10.1101/2022.02.21.22271298 doi: medRxiv preprint Sex All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The red line indicates vaccine effectiveness estimates for every 2-week interval during the study period and the 95% CI are shaded in grey. Both symptomatic and asymptomatic infections were included. The dashed horizontal line indicates the start of Delta period.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Protection during pre-delta period is in red while protection during delta period is in blue. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted February 22, 2022. ; https://doi.org/10.1101/2022.02.21.22271298 doi: medRxiv preprint